Serum soluble Fas in the syndrome of hemolysis, elevated liver enzymes, and low platelets

OBJECTIVE: To assess whether serum levels of soluble Fas and soluble Fas ligand are altered in the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) METHODS: Serum samples from 22 pregnant women diag nosed with HELLP syndrome were compared with sera from 37 healthy women with noncomplicated. singleton pregnancies. Serum levels of soluble Fas and soluble Fas ligands were determined by enzyme immunoassay. Student A chi (2), Pearson's correlation coefficient, and multiple regression tests were used for statistical analyses. RESULTS: Both soluble Fas and soluble Fas ligand were detected in the sera of normal pregnancies as well as in those with HELLP syndrome. The mean serum level of soluble Fas was significantly higher in women with HELLP syndrome than in healthy gravidas (10.75 +/- 0.93 versus 5.81 :+/- 0.37 U/mL, P < .001). However, there was no significant difference in mean serum soluble Fas ligand levels of the two group, (0.60 +/- 0.06 compared with 0.50 +/- 0.22 ng/mL, P = .23). In women with HELLP syndrome, there were no significant correlations between serum levels of soluble Fas or soluble Fas ligand with liver transaminases (aspartate and alanine aminotransferase) and platelet count. CONCLUSION: Serum levels of soluble Fas, but not soluble Fas ligand, are significantly higher in women with HELLP syndrome than healthy gravidas. ne source of elevated serum levels of soluble Fas in HELLP syndrome remains to be determined. (C) 2001 by the American College of Obstetricians and Gynecologists.